The Goldman Sachs Group Inc (NEOE:GS)
C$ 28.94 0.52 (1.83%) Market Cap: 263.00 Bil Enterprise Value: 564.60 Bil PE Ratio: 17.20 PB Ratio: 1.70 GF Score: 50/100

Kronos Bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-15-2023 10:40 AM Transcript

Jun 15, 2023 / 05:40PM GMT
Release Date Price: C$17.33 (-0.40%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good morning, everyone. Thanks for joining us. Really pleased to have with us the Kronos team. We have Norbert Bischofberger, President and CEO; Yasir Al-Wakeel, CFO and Head of Corporate Development; and Jorge DiMartino...

Charles Lin
Kronos Bio, Inc. - SVP of Biology

I'm Charles.

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Actually, Charles. sorry.

Charles Lin
Kronos Bio, Inc. - SVP of Biology

Jorge couldn't make it.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Yes. Yes. Yes. So maybe to start here. KB-0742, your CDK inhibitor, is the first molecule to emerge from your platform. Can you start by walking through the key takeaways for the first -- from the first data release that you provided as well as the rationale for your Phase II dose selection?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot